Why Now Is A Great Opportunity To Take Profit On Takeover Target Smith & Nephew plc

Smith & Nephew plc (LON:SN) is not an opportunity at this price, argues this Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Smith & Nephew (LSE: SN) (NYSE: SNN.US) is on a roll. If you are invested and you are perhaps tempted to cash in now, you may well be right. Here’s why. 

Performance/Premium

S&N shares have risen 7% since 23 December, when it was rumoured once again that S&N would be taken over by Stryker for about £13bn ($20bn). According to Bloomberg sources, S&N’s equity could be valued at almost 1,400p, for an implied 20% premium from its current level.

How realistic is such a price tag, though?

Should you invest £1,000 in Hargreaves Lansdown right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Hargreaves Lansdown made the list?

See the 6 stocks

Firstly, S&N stock should trade below 900p to draw interest from investors, in my view.

Secondly, S&N is a prized asset but its shares had already gained 30% of value before Christmas Eve on the back of takeover rumours rather than meaningful operational improvements in 2014.

Value 

S&N’s share price rallied (+25%) to 1,100p in less than eight weeks to 10 June 2014. In those days, Zimmer had agreed to acquire Biomet for $13 billion, so investors decided to pay up for other takeover targets such as S&N in the sector. 

Based on S&N’s enterprise value (EV) divided by revenue, and EV/adjusted operating cash flow, the shares already trade in line with their mid-cycle multiples — and also trade at an implied 25% discount to peak-cycle multiples. In short, they are pretty expensive. 

While consolidation for medical device makers is on the cards, it’s unlikely that any buyer would be willing to offer a meaningful premium to S&N’s current valuation of 1,165p — although, admittedly, S&N could be broken up, while certain assets could be flipped to private-equity firms at a marked-up price. 

Another issue is that a tax-inversion deal isn’t likely to happen any time soon, although a smaller number of bigger players are competing in a sector where Medtronic and Johnson & Johnson may also decide to grow their asset base inorganically and, equally important, could deploy lots of cash held abroad.

S&N Is Not Cheap 

A full bid at 1,400p a share would value S&N at almost £13bn, for an implied forward adjusted operating cash flow multiple of about 11x — which seems a rich valuation for a business whose cost-cutting potential is more attractive than its organic growth prospects at this point in the business cycle. 

S&N stock is currently valued at a high multiple of 29x forward earnings, and trades 5% above the average price target from brokers, which are bullish, of course, about M&A prospects in a sector where rising costs point to more deal-making to preserve operating margins. Both S&N and larger players must also preserve market share as hospital consolidation in the US leads to lower budgets, which in turn puts pressure on suppliers’ profits. 

Yet do you recall what happened to the value of Shire when merger talks with AbbVie collapsed in October 2014? I would bet on a similar, painful outcome for S&N shareholders this year… 

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has recommended Glaxo and Shire. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Calendar showing the date of 5th April on desk in a house
Investing Articles

Here’s how a £20k ISA could produce £1,580 of passive income in the next year

A Stocks and Shares ISA stuffed with dividend shares can be a lucrative source of passive income. Christopher Ruane explains…

Read more »

Investing Articles

Prediction: 12 months from now, £5,000 invested in Tesla stock could be worth…

Tesla stock has endured a miserable year so far, falling by 29%. Muhammad Cheema takes a look at how it…

Read more »

Investing Articles

See what £10,000 invested in Tesla shares at their mid-December peak is worth today 

As the world absorbs the full scale of Donald Trump's tariffs, Tesla shares are reeling. Investors who bought the stock…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

2 investment trusts to consider for a Stocks and Shares ISA

These two investment trusts have a different focus -- but our writer sees both as worth considering, one more for…

Read more »

Investing Articles

Deutsche Bank reiterates Buy rating on 9.6% yielding FTSE 250 stock that was “most shorted in UK”

Our writer investigates why a major broker remains optimistic about a FTSE 250 stock that was once the most shorted…

Read more »